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ttp://dx.doi.org/10.1016/j.ajpath.2014.02.003A hallmark of idiopathic pulmonary ﬁbrosis (IPF) is excessive and disordered deposition of extracellular
matrix. Although the lung extracellular matrix normally plays an essential role in development and mainte-
nance of lung tissue through reciprocal interactions with resident cells, the disordered matrix in the diseased
lung is increasingly recognized as an active and important contributor to IPF pathogenesis. This working
group summary from a recently conducted National Heart, Lung, and Blood Institute strategic planning
workshop for IPF research highlights recent advances, challenges, and opportunities in the study of matrix
biology in IPF. Particular attention is given to the composition and mechanical properties of the matrix in
normal and diseased lungs, and the biochemical and biomechanical inﬂuences exerted by pathological matrix.
Recently developed model systems are also summarized as key tools for advancing our understanding of
matrix biology in IPF. Emerging approaches to therapeutically target the matrix in preclinical and clinical
settings are discussed, as are important concepts, such as alterations of the matrix with aging and the
potential for the resolution of ﬁbrosis. Speciﬁc recommendations for future studies in matrix biology of IPF
are also proposed. (Am J Pathol 2014, 184: 1643e1651; http://dx.doi.org/10.1016/j.ajpath.2014.02.003)A guest editor acted as the editor-in-chief for this manuscript. No person
at the University of Alabama at Birmingham was involved in the peer re-
view process or ﬁnal disposition for this article.
Disclosures: None declared.The structural and social organization of cells into functional
units within tissues/organs of multicellular organisms re-
quires adhesion to their neighbors and to the acellular extra-
cellular matrix (ECM). The matrisome, composed of almost
300 ECM proteins, is one of the most plastic and rapidly
evolving compartments of the proteome.1 In addition to
providing essential physical scaffolding for cellular con-
stituents, the ECM serves to integrate biochemical and
biomechanical cues essential for tissue morphogenesis,stigative Pathology.
.differentiation, and homeostasis.2 ECM deposition, remod-
eling, and resorption are dynamic processes that are precisely
orchestrated and controlled during normal development, ho-
meostasis, and tissue repair. Loss of control of these processes
Thannickal et almay lead to pathological tissue remodeling, as in emphysema
or idiopathic pulmonary ﬁbrosis (IPF). A hallmark of IPF is
the formation of a stiff, ﬁbrotic ECM that obliterates normal
alveolar structures and impairs gas exchange. In November
2012, the National Heart, Lung, and Blood Institute convened
a workshop in Bethesda, MD, to outline future directions and
priorities for research in IPF. This workshop summary high-
lights recent advances in our understanding of the active role
of the ECM in determining the phenotype and fate of lung
cells participating in tissue repair, as well as the challenges
and opportunities that will allow studies of the ECM to inform
future diagnostic tools and therapeutic approaches in IPF.
The ECM in Lung Development and Aging
A central role for the ECM in cell speciﬁcation and fate
determination during normal lung development is well
appreciated.3 Branching morphogenesis, alveolar septation,
and terminal differentiation of the various cells of the lung
are all dependent on proper ECM signals.4 Maintenance of
cell polarity and regulation of surfactant synthesis by type II
alveolar epithelium are dependent on the ECM, including its
three-dimensional (3D) and topographic cues.5 The concept
of an aberrant recapitulation of lung development in IPF
has been proposed,6,7 although mechanisms are not well
deﬁned. Understanding the differences in lung ECM
composition and organization during development and in
postnatal life may provide insights into mechanisms of the
aberrant remodeling in IPF.
IPF is a disease of aging,8 yet studies on ECM composi-
tion, topography, or stiffness of the aging lung are lacking. In
aging tissues, collagen ﬁbers may be prone to inappropriateFigure 1 Biochemical and biomechanical interactions between ﬁbroblasts and t
initiate intracellular signals through multiple pathways. Integrin, microﬁlament,
promote the ﬁbrogenic phenotype of ﬁbroblasts. Reciprocally, cellular signals can fe
the ECM. These bidirectional interactions between ﬁbroblasts and the ECM provide
TAZ, transcriptional coactivator with PDZ-binding motif; YAP, yes-associated prote
1644cross-linking, which leads to tissue stiffening and decreased
elasticity.9 Oxidative stress associated with aging may in-
ﬂuence this process,10e12 although the relative contributions
of enzymatic and nonenzymatic mechanisms of ECM cross-
linking to disease pathogenesis require further study.
ECM Composition and Its Bioactive Components
The ﬁbrotic ECM in IPF is composed of a variety of mol-
ecules that include proteins, glycoproteins, proteoglycans,
and polysaccharides, each of which has distinct biochemical
and biomechanical properties (Figure 1). The ﬁbrotic matrix
in IPF tissue is rich in ﬁbrillar collagens, including type I and
III collagen, proteoglycans, such as hyaluronan, and various
glycoproteins, prominent of which is cellular [extra domain
(EDA)-containing] ﬁbronectin.13e15 During physiological
repair, ﬁbrillar type I (polymerized) collagen functions to
limit ﬁbroblast proliferation through the activation of key
phosphatases via engagement of the a2b1 integrin.16e18 This
physiological restraint may be lost in IPF ﬁbroblasts,19,20
which potentially contributes to their expansion in patho-
logical ﬁbrosis. These studies suggest that cell-autonomous
phenotypes and behavior inﬂuence cell-matrix interactions.
Ultrastructural studies indicate that ﬁbroblastic foci are
composed of myoﬁbroblasts within an ECM rich in collagen
and EDA-ﬁbronectin.15 EDA-ﬁbronectin has been reported to
be required for the myoﬁbroblast differentiation by trans-
forming growth factor-b1 (TGF-b1)21 and cellular motility.22
Although the mice deﬁcient in EDA-ﬁbronectin are protected
from bleomycin-induced ﬁbrosis, they succumb early to unre-
mitting inﬂammation,23 supporting important roles for ﬁbro-
nectin and its spliced variants in the control of inﬂammation andhe ECM. Biochemical and biomechanical stimuli derived from the ﬁbrotic ECM
and transcription factoremediated signals are highlighted. These signals
edback to the ECM and regulate the composition and mechanical properties of
positive feedback loops that sustain/perpetuate progression of lung ﬁbrosis.
in.
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Matrix Biology of IPFﬁbrosis. Periostin is another glycoprotein that is overexpressed
in IPF lungs, regulates proﬁbrotic ﬁbroblast phenotypes, and
promotes ﬁbrogenesis in experimental models.24
Hyaluronan (HA) is a large-molecular-weight glycosami-
noglycan that is synthesized by HA synthases (HAS). It is
widely expressed during tissue injury and remodeling. HA and
HA fragments accumulate at sites of tissue injury and play
pivotal roles in normal wound healing and ﬁbrosis.25 When
HAS2 is overexpressed in myoﬁbroblasts, severe ﬁbrosis de-
velops after lung injury in mice; silencing of HAS2 or inhibi-
tion of CD44, a cell surface proteoglycan receptor, inhibits IPF
ﬁbroblast invasion.26 These data provide evidence that HA-
CD44 interactions regulate IPF ﬁbroblast motility and inva-
sion, which may be critical for pathological remodeling in IPF.
Taken together, these studies indicate that speciﬁc ECM
components, such as type I collagen, EDA-ﬁbronectin, peri-
ostin, and hyaluronan, are critical regulators of ﬁbroblast
phenotypes and ﬁbrogenesis. A disease-speciﬁc, contextual
understanding of these ECM signals via integrins and pro-
teoglycan cell surface receptors will uncover therapeutic
strategies to halt or slow ﬁbrotic progression.
Biomechanical Signaling by the ECM
In addition to its chemical composition, ECM dimension-
ality, organization/topography, and mechanical properties
inﬂuence cellular phenotypes and fates that promote
ﬁbrosis. Our current understanding of ECM mechanics in
normal and IPF lungs is limited. For example, the long held
assumption that lung elasticity can be partitioned into con-
tributions from elastin at low volume and collagen at high
volume is likely an oversimpliﬁcation.27,28 At the organ
scale, lung mechanical properties are typically reported as
compliance (or elastance) measured from pressure-volume
relationships, and at this level, there is evidence, althoughFigure 2 Potential matrix-directed therapeutic strategies for lung ﬁbrosis.
The American Journal of Pathology - ajp.amjpathol.orgnot universal, that ﬁbrosis is associated with decreases in
lung compliance (increased stiffness). Such measurements
that treat the lung as a homogenous continuum do not
address the heterogeneity of tissues at the regional, cellular,
and molecular levels. Newer technologies, such as atomic
force microscopy microindentation, allow for measurements
of tissue/cellular stiffness.14,29 Interestingly, application of
atomic force microscopy to isolated lung epithelial cells
shows that the cytoplasm of type II cells is stiffer (approx-
imately twofold median difference) than that of type I
cells,30 whereas ﬁbroblast stiffness increases with age.31
Within the remodeled ﬁbrotic ECM itself, we have rela-
tively little understanding of how mechanical properties are
perturbed, and whether this arises from changes in composi-
tion, density, cross-linking, other post-translational modiﬁ-
cations, or some combination of these. Most studies of tissue
mechanics (in the normal and diseased states), thus far, have
focused onmatrix stiffness or elasticity. Tissues, however, are
viscoelastic and nonlinear, meaning that incremental strain
(change in dimension normalized to some initial dimension)
changes with time and strain levels as stress is applied; both of
these properties may be altered during ECM remodeling.32
Interestingly, ﬁbroblasts change their mode of 3D migration
depending on whether matrices exhibit linear or nonlinear
elastic properties, demonstrating one important inﬂuence of
matrix physical properties on ﬁbroblast phenotype.33 Me-
chanical characterization of the lung ECM requires replication
of surface tension effects within the intact lung microstructure
and the distending prestress normally present in the thoracic
cavity. Intravital microscopy may open opportunities to
visualize events within the alveoli andmicrovasculature of the
intact lung.34 In addition, newer applications of noninvasive
imaging modalities, such as microfocal X-ray computed to-
mography,35 magnetic resonance elastography,36 and tran-
sient elastography,37 may allow for assessments of tissue1645
Table 1 ECM Model Systems
Variable Uses Advantages Limitations
In vitro
Tissue culture plastic
coated with puriﬁed
ECM
Identify direct ECM
receptor interactions;
study signaling
pathways and ECM
effects on cell behavior
Study the function of a specific ECM
molecule or receptor; trace
downstream effects from ECM
adhesion to biological responses;
precise definition of phenotypic
responses to ECM molecules
Coating on plastic likely changes ECM
conformations; planar surface
prevents determining effects in a
3D environment; stiffness of tissue
culture plastic is significantly
higher than physiological range;
unable to assess effects of multiple
ECM proteins in a physiological
mixture
Tissue culture plastic
coated with ECM from
homogenized tissue
Identify effects of tissue
ECM on cell behavior;
understanding roles of
simultaneous signaling
by multiple ECM
proteins
Interrogation of ECM adhesion
signaling; precise definition of
phenotypic responses to mixtures of
ECM molecules in physiological
ratios; assess the role of receptors
using function-blocking strategies
Coating on plastic likely changes ECM
conformations and relationships
between proteins in the mixture;
planar surface prevents
determining effects in a 3D
environment; stiffness of tissue
culture plastic is significantly
higher than physiological range
Mechanically tunable
acrylamide and other
hydrogels
Identify effects of ECM on
cell behavior under
physiological or
pathological stiffness
Allows for the study of matrices of
varying stiffness, potentially in
gradients; depending on the hydrogel
system, stiffness may increase or
decrease with time in culture; can be
coated with single or multiple
proteins or protein mixtures;
different ECM proteins can be
presented in different patterns
Planar surface prevents determining
effects in a 3D environment;
mixtures of proteins may not
interact physiologically after cross-
linking to hydrogel; cross-linking
may alter ECM protein conformation
Type I collagen gels Study cell behavior as it
relates to collagen I;
can study cell
contractility in 3D
Cells can be implanted within the gel,
accounting for dimensionality;
studies of proteolysis, cell migration,
and other cell behaviors are possible;
multiple imaging modalities available
for determining effects of live cells
on collagen organization
Studies primarily limited to effects
from collagen I; unable to control
stiffness of the gel
Basement membrane
extract gels
Studies of cell behavior
in 3D
Can be used both in vitro and in vivo;
supports growth of mesenchymal,
endothelial, and epithelial cells
ECM content and growth factor
content vary lot to lot;
commercially available
preparations largely derived from
murine tissue (human tissue
preparations now available)
Fibroblast- or other cell-
derived matrices
Studies of cell behavior
in 3D
Fibroblasts or other cells can be
extracted, leaving behind a 3D matrix
of varying proteins, in a
physiological orientation; matrices
can be reseeded with cells of choice
Unable to control stiffness of matrix,
which may be reflected from the
underlying tissue culture plastic
substrate; does not account for ECM
derived from other cell types;
potentially technically difficult
Polyelectrolyte
multilayers
Identify direct ECM
receptor interactions;
study signaling
pathways and ECM
effects on cell behavior
Allows control of physical properties of
the culture system; proteins
potentially interact in a physiological
way; protein mixtures more uniform
than with other methods
Potentially technically difficult; may
be difficult to control stiffness of
the system; does not permit study
of cells in 3D
In vivo
Basement membrane
extract gels
Studies of cell behavior
in 3D
Can be used both in vitro and in vivo;
supports growth of mesenchymal,
endothelial, and epithelial cells;
other matrix proteins and cells can be
mixed in
ECM content and growth factor
content vary lot to lot;
commercially available
preparations derived from murine
instead of human tissue
(table continues)
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Table 1 (continued )
Variable Uses Advantages Limitations
Ex vivo
Acellular human (or
experimental animal)
matrix
Study effects of ECM on
cell behavior using
human (or experimental
animal)e, organ-, and/
or disease-specific
matrices; can be used to
study tissue
regeneration
Uses human (or experimental animal)
ECM in an organ- or disease-specific
manner; can be processed to provide
uniform disks of matrix; retains
dimensionality and stiffness of the
native organ; retains a proportion of
normal ECM composition and growth
factor inclusion; a single human
organ can provide a multitude of
disks for study; experimental animal
tissue is relatively easy to obtain
Human tissue can be difficult to
obtain; complete decellularization
must first be confirmed;
compositional differences may be
present in tissues from donors of
different ages; some ECM
components may be lost during the
decellularization process
Matrix Biology of IPFbiomechanical properties of the lung in vivo. Transient elas-
tography has already been applied to the study of liver disease.
The Fibroscan (Echosens, Paris, France) is an ultrasound-
based device that uses vibration-controlled transient elastog-
raphy by which a controlled vibration produces a mechanical
shear wavewith consistent amplitude and frequency. By using
low-frequency ultrasound, the speed and depth of shear wave
propagation through the tissue are recorded and represented in
graphic form and as Young’s modulus (stiffness).37 Similarly,
magnetic resonance elastography uses amagnetic resonancee
compatible ultrasound to generate mechanical waves through
the liver, which are then measured using a standard 1.5-T
magnetic resonance imager with a modiﬁed phase-contrast,
gradient-echo sequence. The wavelength visible on the
readout can then be used to generate elastograms (maps of
tissue stiffness) and calculate local Young’s modulus.38
Several groups have shown that ﬁbroblast function and
myoﬁbroblast differentiation are tightly linked to the
deformability (rigidity and stiffness) of the ECM.29,39e42
Intriguingly, several of these studies indicate that the ef-
fects of matrix stiffness may be independent of soluble
proﬁbrotic factors, such as TGF-b, or may selectively pro-
mote the effects of these factors.29,39,41 In addition to matrix
stiffness, interstitial ﬂuid ﬂow43 and stretch44 may also
regulate ﬁbroblast signaling and differentiation.
Both the outside-in transmission of mechanical forces to
the cell and the inside-out transmission of traction forces
from the cell to the ECM fundamentally involve the cyto-
skeleton. Force transmission in both directions ﬂows
through focal adhesions (FAs), which link the cytoskeleton
with the ECM through transmembrane integrin receptors.
FA assembly itself is greatly augmented by both forces
applied externally to cells and forces generated in cells
internally by myosin-driven contraction.45 Both externally
applied and internally produced forces transmitted by the
cytoskeleton generate biochemical signals by inducing FA
protein conformational changes that activate FA kinase.45
Adhesion signaling via FA kinase is essential for
TGF-b1einduced myoﬁbroblast differentiation46 and sur-
vival,47,48 as well for the induction of mechanical force-
induced hypertrophic scarring of the skin.49The American Journal of Pathology - ajp.amjpathol.orgIn addition to FA signaling, actin cytoskeletal dynamics are
sufﬁcient to activate transcriptional programs that regulate
proﬁbrotic genes. The myocardin-related transcription factors
(MRTFs), MRTF-A and MRTF-B, have been identiﬁed as
important links between actin dynamics and gene expression
(Figure 1).50 MRTF-A has recently been demonstrated to be
required for intrinsic matrix stiffness-induced ﬁbroblast
a-smooth muscle actin expression and myoﬁbroblast differ-
entiation.41 Signaling by the Rho GTPase RhoA and its
downstream Rho-associated coiled-coileforming kinases,
ROCK1 andROCK2, regulates effector proteins thatmodulate
the polymerization equilibrium of G- and F-actin, and conse-
quently regulateMRTF nuclear translocation.50 Recent studies
demonstrate that inhibition of this mechanosensitive signaling
pathway induces myoﬁbroblast apoptosis by the intrinsic
mitochondrial pathway and ameliorates experimental pulmo-
nary ﬁbrosis.51 Other mechanosensitive pathways that are
relevant to ﬁbrosis include the Wnt/b-catenin pathway52,53;
yes-associated protein and transcriptional coactivator with
PDZ-binding motif, downstream effectors of the Hippo
pathway54; and ion channels.55 Further studies on therapeuti-
cally tenable biomechanical signaling pathways that sustain
proﬁbrotic cellular phenotypeswill lead tonovel, andhopefully
more effective, therapies for ﬁbrosis.ECM Dynamics and Fibrosis Resolution
The process of ﬁbrosis is dynamic and best described as a
process of continuous matrix remodeling, which results in
net ECM deposition. For example, the collagenous matrix of
the rabbit lung turns over by as much as 10% per day under
homeostatic conditions,56 and the rapid accumulation of
collagen after lung injury is the result of increased rates of
collagen synthesis and decreased rates of degradation.57 The
mechanisms that lead to an imbalance in ECM synthesis/
deposition and degradation in IPF are not well understood.
There is evidence that ﬁbrosis of diverse organ systems,
such as the liver, kidney, and heart, are at least partially
reversible in experimental animal models and in
humans58,59; similar observations have been made in lung1647
Thannickal et alﬁbrosis.60,61 Indeed, survivors of acute respiratory distress
syndrome, which is associated with variable degrees of
ﬁbrosis and restrictive physiological features, demonstrate
almost complete restoration of normal lung function, be-
tween 3 and 6 months after lung injury.62 For resolution of
ﬁbrosis to occur, at a minimum, recruited/activated myoﬁ-
broblasts must be eliminated and the deposited ECM must
be degraded and cleared; in most cases, it appears that both
of these processes occur synchronously.63
Although the origin of myoﬁbroblasts has received much
attention in recent years,64 mechanisms that control the fate of
myoﬁbroblasts are largely unknown. Elimination of myoﬁ-
broblasts during ﬁbrosis resolution may involve apoptosis,63,65
dedifferentiation,66,67 or elimination by immune cells.68 Which
of these mechanisms are subverted in IPF is not known.
Myoﬁbroblasts acquire an apoptosis-resistant phenotype in
IPF, and multiple mechanisms have been proposed69,70; an
understanding of how myoﬁbroblasts evade apoptosis or
potentially lose the capacity for dedifferentiation may provide
new opportunities for therapeutic intervention.
Although one might surmise that net ECM deposition is
due to a relative deﬁciency in ECM degrading enzymes,
evidence suggests far greater complexity.71 Indeed, several
studies demonstrate increased collagenase activity and the
expression of several other matrix metalloproteinases in
IPF.72,73 The plasminogen activation system also participates
in injury repair, and through modulation of proteolytic and
nonproteolytic functions, plasminogen activator inhibitor-1
may contribute to ﬁbrosis.74,75 Macrophage subpopulations
participate in this process and may facilitate ﬁbrosis resolu-
tion.76 It remains to be determined whether the IPF matrix is
intrinsically resistant to proteolytic degradation. Interest-
ingly, mice harboring a cleavage-resistant form of collagen I
fail to demonstrate regression of liver ﬁbrosis.77 Thick,
acellular scars and those with extensive collagen and elastin
cross-linking (via the action of tissue transglutaminases, lysyl
oxidases, and other cross-linking enzymes) may be more
resistant to degradation and ﬁbrosis resolution.78Therapeutic Targeting of the Matrix and Matrix
Sensing
Given the essential role of the ECM in the initiation and
progression of ﬁbrosis, therapeutic strategies that target the
matrix or its sensing by lung cells may prove beneﬁcial in
halting or even reversing ﬁbrosis (Figure 2). Pharmacolog-
ical agents that inhibit ECM synthesis, deposition, and sta-
bilization or promote its degradation are now being
developed; many have shown to be efﬁcacious in preclinical
models and a few have reached phase 1 and even phase 2
clinical trials. Potential matrix-directed therapeutic targets
include the following: cytokines that activate ECM-
producing lung cells79; matrix metalloproteinases73;
plasminogen activation74; integrins80; matrix-sensing intra-
cellular proteins51; and matrix cross-linking enzymes, such1648as tissue transglutaminase-281 and lysyl oxidase.82 Success
with therapeutic approaches that target the ECM and matrix
sensing will be bolstered by further studies of the IPF matrix
and mechanisms that drive aberrant ECM remodeling, as
well as the availability of selective pharmacological agents.ECM Model Systems
The translation of the accumulating knowledge of matrix
biology to the development of new diagnostic biomarkers and
therapeutic agents for IPF will be facilitated by improved
in vitro, in vivo, and ex vivo model systems. Ideally, these
systems must replicate key features of the in vivo IPF lung, in
particular its dimensionality, stiffness, and matrix composition.
Classically, studies of the ECM use tissue culture plastic dishes
coated with a single ECM protein (or mixture of proteins) on
which cells are cultured. This approach has been informative
for purposes of identifying receptors, elucidating signaling
pathways, and understanding the fundamental biological pro-
cesses. However, in vivo, cells reside in the 3D environment
that is neither as planar nor as stiff as a tissue culture plastic, and
includes a complex mixture of ECM proteins.
There are now a variety of culture systems available that
mimic the mechanical properties and dimensionality of tis-
sues in vivo (Table 1). One widely used system is me-
chanically tunable polyacrylamide gels with variable
concentrations of bis-acrylamide, which imparts known
degrees of stiffness to the matrix.29,39,41,83,84 These matrices
can be coated with puriﬁed ECM proteins or mixtures to
provide a biologically relevant culture substrate with
appropriate (normal) or augmented (ﬁbrotic) stiffness. A
limitation of this system is that cells can be cultured only in
two dimensions. Newer materials are being developed that
permit cell growth in 3D, and that enable gradual softening
or stiffening. Other such matrix models in or on which cells
can be cultured (eg, type I collagen gels) exist. Another
approach that may provide some degree of dimensionality
and more physiological stiffness is to extract cell-derived
matrices from ex vivo ﬁbroblast cultures, followed by
reseeding of the cells to be studied.33 These techniques (or
combinations thereof) may address difﬁcult-to-answer
questions regarding the role of both composition and
dimensionality of the ECM in regulating proﬁbrotic cellular
phenotypes. Research is urgently needed, however, to
develop additional culture systems that not only enable
study of mechanical stiffness in a 3D environment but also
incorporate other biomechanical factors, including viscosity,
ﬂow, stretch, and hydrostatic pressure.
Another model being used to study the effects of ECM on
lung cell biology is the acellular human lung ECM. In this
system, human lungs from normal donors or patients with
IPF are decellularized using a series of detergent, salt, and
DNase washes. Subsequently, tissues are sliced on a
vibratome to generate individual culture disks that retain
both their native stiffness and ECM composition.14 Thisajp.amjpathol.org - The American Journal of Pathology
Matrix Biology of IPFmodel system has multiple advantages, including that it
incorporates a human matrix and allows investigators to
study matrices from the disease of choice, or in relevant
animal models; more important, it mimics the matrix orga-
nization, mechanics, and dimensionality of the lung micro-
environment. Other methods for generating mixtures of
matrix proteins (eg, polyelectrolyte multilayers) and study-
ing individual matrix proteins or simple protein mixtures
(eg, collagens and proteoglycans) in mechanically tunable
systems need to be developed.
Among other aspects of ECM biology in IPF that remain
poorly understood are the factors affecting the capacity of
ECM to bind growth factors and growth factorebinding
proteins (eg, latent TGF-b binding proteins). Although much
has been gleaned from basic biochemical investigations with
respect to the molecular interactions through which these
factors bind ECM, little is known about how stiffness,
stretch, and ﬂuid ﬂow (eg, tissue ﬂuid ﬂow, cyclic stretch of
lung ECM, hydrostatic pressures, and elastin cross-linking)
affect binding capacity of these proteins to the ECM. Thus,
development of models that can account for these various
features will almost certainly enhance our knowledge and
provide more realistic platforms on which to test hypotheses
regarding the ECM in IPF and lung ﬁbrogenesis.
Recommendations
On the basis of the working group summary, we recommend
further studies to: i) characterize the alterations of the IPF lung
ECM in relation to composition, organization, topography, and
stiffness; and determine how each of these may inﬂuence
speciﬁc proﬁbrotic cellular phenotypes; ii) determine genetic,
epigenetic, age, and environmental factors that may account
for the altered IPF lung ECM; iii) identify key ECM proteins
and their receptors, which promote and perpetuate ﬁbrotic
remodeling (eg, the invasive ﬁbroblast phenotype, aberrant
proliferation, and cellular senescence); iv) elucidate the
mechanisms that promote matrix stiffening (eg, the role of
matrix cross-linking enzymes) and determine how stiffness
sensing is transmitted to ﬁbrogenic signals; v) determine the
extent to which ﬁbrosis resolution occurs in the lung and
strategies that may be used to reverse established ﬁbrosis,
including, but not limited to, the induction of myoﬁbroblast
apoptosis, dedifferentiation, and immune surveillance; vi)
facilitate the development of matrix-directed therapeutics,
including proof-of-concept studies in preclinical cell/animal
models and early-phase clinical studies in IPF; and vii) develop
model systems that simulate the in vivo lung ECM environment
for basic studies of lung cell biology and preclinical testing.
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